ArticleMedicine2025
Developing a predictive model for the efficacy of neoadjuvant chemoradiotherapy in locally advanced rectal cancer using multiparametric magnetic resonance imaging: An innovative approach.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A predictive model was constructed based on traditional clinical magnetic resonance imaging (MRI) data to effectively predict the efficacy of neoadjuvant chemoradiotherapy (NCRT) for locally advanced rectal cancer (LARC). A retrospective analysis was conducted on the clinicopathological and imaging data of patients who underwent MRI prior to NCRT at Nanjing Traditional Chinese Medicine Hospital between April 2022 and June 2024. A total of 149 patients with histologically confirmed LARC were included. Based on the tumor regression grade (TRG) criteria for rectal cancer, patients were classified into TRG0 (n = 31), TRG1 (n = 34), TRG2 (n = 50), and TRG3 (n = 34). All patients underwent rectal MRI before treatment, and the imaging parameters (baseline status) were extracted. A predictive model based on multiparametric MRI indicators was developed to assess and predict the efficacy of neoadjuvant therapy in LARC. Statistically significant differences (P-values < .05) were observed in the imaging parameters, including the maximum sagittal tumor diameter, apparent diffusion coefficient (ADC), number and maximum diameter of lymph nodes, node stage, extramural vascular invasion, and circumferential resection margin (CRM), before and after treatment. A prediction model was constructed based on ablation experiments, and the best predictive performance was achieved when the feature combination included the maximum sagittal tumor diameter, ADC, maximum lymph node diameter, node stage, and CRM. The average classification accuracy, area under the curve, sensitivity, and specificity reached 87.53%, 0.85, 81.26%, and 79.32%, respectively. Among the top 50 ablation experiments ranked by predictive performance, the maximum sagittal tumor diameter, ADC, and node stage had higher proportions in the feature combinations. The prediction model constructed by using the optimized attention mechanism method has a high accuracy rate in predicting the therapeutic effect of LARC based on traditional clinical imaging data.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.